Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Crispr Therapeutics

3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.

This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.

Cathie Wood recently added to her position in CRISPR Therapeutics stock.

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high cholesterol

The Independent UK

This Leading Gene-Editing Stock Could Be Going Private. Should You Buy Its Shares First?

CRISPR Therapeutics is the subject of strong buyout speculation after earning FDA approval for a breakthrough gene-editing therapy.

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

CRISPR Stock Surges in Recent Weeks: What's Going On?

CRISPR Therapeutics AG (NASDAQ:CRSP) is trending Thursday, up more than 45% over the past month. Here’s a look at what’s driving the move.

inkl

Read news from The Economist, FT, and more,
with one subscription

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025

Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Markets Today: Stock Index Futures Climb on Dovish PPI Surprise

Markets Today: Stock Index Futures Climb on Dovish PPI Surprise

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.21%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.37%. U.S. stock index futures this morning are moderately higher after U.S. Mar producer prices rose less than expected, easing inflation concerns. Also, weekly jobless claims rose...

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Gilead Sciences

the American Heart Association

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Recursion Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

366,907 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play